Ventrus BioSciences, Inc. (Nasdaq: VTUS; Twitter: $VTUS) hosted a conference call this morning about Friday's press release (see Friday's ProActive write-up) on the revised protocol. The U.S. Food and Drug Administration (FDA) recommended, under a Special Protocol Assessment (SPA), new and more robust definitions for efficacy endpoints.